Let's hope so. I seriously wonder what people are waiting for. I've said it many times -- NXEN has several key 'ingredients' of OTC stocks that run WILD even without official news. Seriously, completely bankrupt stocks with the 'Q' on the end have WILD runs on TOTAL speculation.

I suppose once more people feel comfortable that the catalysts are truly happening (or maybe they'll wait for the official news), maybe then we'll see some closet shareholders pumping on Twitter. Haha.

I touched on this in one of my first NXEN blogs:

I don't know if it's true to say NXEN is using 'synthetic cannabis' -- they're just researching non-THC components is all. Cannabinoids.

"Nexien is researching the use of cannabinoid receptor modulators, terpenes, and other ingredients"

https://nexienbiopharma.com/research_development

I hope you've been able to average down in this $0.17 - $0.20 range. That will help a lot when NXEN returns to $0.50 - $1.50 on news/updates.

It may take a while. It may not. All depends on whose eyes are on this stock when things happen.

Again, I remind everyone of the pure trash that runs crazy on the OTC for the dumbest of reasons. If legit news drops soon, the float here is VERY small in comparison to the other crap that runs 500% - 1,000%.

Time will tell. I bought, added, and held because of the management and the things we've heard to date. Things no doubt take time to execute. I've been a business owner for 18 years and (almost) nothing big happens with the snap of a finger.

I actually just Tweeted about this, ironically.

I'm long on both $NXEN and $OWCP, but I honestly didn't expect $OWCP to be at a higher share price -- because $NXEN has 1/3rd the O/S and 95% smaller float!

$OWCP definitely has some exciting things coming out soon, but $NXEN is clearly still VERY overlooked!

I did sell off some OW a while back to buy more NXEN as to diversify and because I thought they'd run sooner -- because this is the OTC where pure-crap stocks run high because an announcement of entering the CBD market. Not sure why THAT is exciting when so many others are going to "sell CBD".

NXEN should be worth far more and I still absolutely believe they're going to be far higher when things start coming out.

As it's been said, a company doesn't control how fast it takes to list on the CSE (or any other exchange). NXEN has done all they can do and now must wait. I'm sure the CRX acquisition definitely restarted the CSE research/DD process and hopefully... We'll see it become official soon.

After having added in the $0.60 range here, I was happy to add at $0.17 too. The management line-up here is still great and full of proven successful people. It's still really early in the game to lose any hope, IMO.

It would be a heck of a move, but that's the kind of move I'm waiting on.

I'm thinking in terms of Market Cap though. I'm also keeping in mind the handful of other medical cannabis / biotechs that have shot up like crazy on certain catalysts.

When OWCP, CNBX, and AXIM went ape-sheet -- they ran to $430M - $600M+ market caps.

The lower O/S and Float here certainly means it's just as possible. But, hopefully on legit news that keeps the share price up that high for a while.

CSE listing could cause a nice spark, but we need some good drug advancement news, IMO. With that talk with the FDA dating back to last year -- I'm really hoping NXEN receives approval to begin clinical trials and maybe receiving Orphan Drug Designation at the same time. That's the kind of thing that can cause those 1,000% gains over the course of days or weeks.

$0.2195 to $2.00 is 811% gain. There are a handful of OTC stocks weekly that see 250% - 1,000% gains in a single day -- sometimes because of splits and non-hype reasons but if you look at the volume you can usually differentiate. Today it was $NXUR, $GRPH, $SPRL, and $ADMG to name a few.

https://www.finscreener.com/screener/top-gainers/stocks/otc

Pascal definitely not the same. They're biotech, not biopharma -- no cannabinoids/cannabis extracts. They're Canadian, not American. Their OTC ticker is Grey Market right now too.

https://www.otcmarkets.com/stock/BIMUF/profile

That's pure manipulation right there.

This article talks about NEXIEN BioPharma!

"US Farm Bill a Boon for Pharma?"

https://www.in-pharmatechnologist.com/Article/2018/12/13/A-boon-for-pharma-Senate-and-House-of-Representatives-approve-hemp-farm-bill?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright

Yeah, management has every reason to minimize dilution -- so capital raise at higher share prices makes their shares worth that much more.

Patience pays. Management knows that.

The OTC has proven to be the most idiotic place.

If only NXEN had more scumbag management, a really high O/S, and 10X the Float... Then maybe people would rush in.

Newbies don't realize that 1,000% gains from 0.20 is still 1,000% profit.

CEO said they've done everything they need to do on their part for CSE... The ball is in the CSE guys court. The listing is imminent.

Will it help? It's anyone's guess since this is the idiotic OTC.

Either way, I'm thankful I've been able to tune out this temporary nonsense. I'm patient.

My honest opinion is our dumper is not Friedland and family -- I've felt all along that he actually knows what NXEN has going for them and wouldn't sell at these levels.

H. Leigh Severance, however, is a 79 year old from Severance Capital Management in Aurora, CO. According to the S-1, he had 1.32 million shares and likely at a cost of around $0.125 like the others.

I could be wrong, obviously. But most of the older generation folks I know would say 100% returns are pretty damn sweet after 18 months.

I wish we had been keeping track of the dumping so we could ballpark how much of 1.32 million could be left.

Isn't there a rule though about notifying shareholders after X amount of time after an event? It's possible, in my OPINION, that they wanted to delay some news until the CSE listing was official -- but since they don't control the CSE timeline and did everything they needed to do, they may have just decided they have to inform shareholders via SEC filing.

Then, move forward with the Ivy League update... But, I don't doubt they'll keep coming with updates after CSE as well.

Oh, nice.

Just curious, how did that whole conversion thing work out on the Reverse Split? I've never bothered to do the math and figure it out.

No kidding? 200k? Dang.

Were you a Private Placement guy?

I haven't heard a word on the extension, so it's my assumption they're going to self-cancel as nobody would buy at $1.00 at this point.

I, for one, bought plenty on the open market since. A buddy of mine has loaded up and more than doubled his holdings on the open market. Everyone I personally know who was a Private Placement investor from the start is definitely holding for several dollars.

I've suspected all along that the CSE listing was what they were waiting on before certain announcements. But, they also don't want to withhold news either.

Ditto.

Can't wait for the CSE news. Maybe that'll wake people up and spark some buying.

The DD is all here. I don't know what people are waiting for.

I still see people talking about RCGP like it's time to load before a run - sparked by a supposed CBD merger. It's already valued CLOSE to NXEN and it's all pure hype. A PINK sheet company with over 500 million shares compared to 55 million.

The OTC is weird. Legit companies don't see the runs the garbage companies do.

Sorry, I don't check iHub overly often some days.

I think Renegades17 gave you a pretty good answer already.

I was going to mention other catalysts that would generate excitement and therefore profits if a person were to trade the action.

If you are wanting to invest in NXEN for the $1 billion market cap that could be coming -- THAT is the part that could take some true patience. But, that's also the type of thing where you wouldn't want to watch the price daily/weekly because it will go up, up, up on good news / advancements and then back down, down, down as people get bored of holding until the next big thing.

OWC is a good example. Though, I maintain OWC shouldn't have run to $3 when it did. That's exactly what hype can do -- we saw it with CNBX and AXIM around the same time.

I do feel NXEN can surely have a crazy, stupid run in the near term with the right type of news as long as it creates a lot of Buy volume. Our float here is so damn small.

But, again, a run to $5 - $10 here in the coming months MAY not "stick" for a long period unless other good stuff continues to come out to keep people excited.

Like Renegades17 said, if NXEN does a deal with GWPH or whoever for XactDose OR if they do a collaboration with GWPH, PFE, JNJ, etc. to do some studies on INJECTABLE cannabinoids for seizures and things -- those types of news items CAN cause some great volume from people truly wanting to INVEST.

But, as we can learn from GWPH's stock price... You will still see the price go back down. There will always be people selling on the news. Some traders are after 25% frequently. Some want 50% - 100% and some try to invest in companies early to hold for 300% - 1,000%.

It's important we all know OUR strategy.

Personally, after seeing OWC run to $3.23 and me not capitalizing on it because I was foolish enough to believe pumpers claiming they're 20-year biotech stock experts and "it's easily going to $8 by Spring and $20 by Winter"... I'm watching MARKET CAP and I will definitely "take profits" on a big run not accompanied by HUGE news. That's my transparency here. I'm an honest guy. :)

I don't want to jinx it, but looking better with Bid at $0.30 and Ask at $0.39 after moving up to $0.34. :)

19,500 dumped twice into the Bid. Congrats to whoever got those.

The stupidity will end eventually.

I just can't imagine how many shares Friedland would have had left.

I pointed out in actual SEC documents that shows he would have forfeited most of his shares when he resigned as CEO... Combined with the fact that Standard Transfer also verified the Float was 1.5M (on 10/23/2018) instead of 2.7M like OTCmarkets.com claimed -- a difference awfully close to the amount Friedland would have forfeited.

So, yes, he would have had a few hundred thousand left I think it was... But shouldn't be just about out of shares by now? Other than the ones his Wife and Kid had.

Here's a list of Ivy League Medical Schools, according to Wikipedia:

https://en.wikipedia.org/wiki/List_of_Ivy_League_medical_schools

I still don't understand why there's not more interest & buying yet.

Since when don't OTC guys like to load up before "imminent news" so they can front load before the run?

Can't help but shake my head every day the volume is low. Especially on news days.

I suppose part of the problem is people are truly lazy when it comes to doing their own DD too.

$NXEN NEWS! Collaboration with Ivy League Medical School!

https://globenewswire.com/news-release/2018/11/28/1658294/0/en/Nexien-BioPharma-And-Ivy-League-University-Medical-School-Collaborate-On-Pre-Clinical-Cannabinoid-Studies.html

Nexien BioPharma Inc. (OTC QB: NXEN) (“Nexien” or the “Company”) announced it is initiating a collaboration with the University Medical School (the “Medical School”) to perform pre-clinical studies using advanced parenteral cannabinoid formulations developed by Nexien, known as NX01R1, NX01R2, and NX01R3 (“formulations”). These formulations target the alleviation of symptoms for the acute treatment and intervention of convulsive disorders and convulsive episodes.

Parenteral administration is a route of administration that includes intramuscular injections of the formulations for optimal dosing and bio-availability. Parenteral administration excludes oral administration of drug formulations.

Nexien will provide the Medical School’s Neurology Lab with specific formulations, in addition to a comprehensive study design developed by the Company’s scientific team. This pre-clinical research will be first performed in rodents, and will initially investigate the Maximum Tolerable Dose (“MTD”) Pharmacokinetic (“PK”) and Pharmacodynamic (“PD”) profiles of advanced cannabinoid-based parenteral formulations.

In November 2017, Nexien filed a provisional patent application with the United States Patent and Trademark Office (USPTO) relating to the use of cannabinoids to treat convulsive disorders, specifically epilepsy and refractory epilepsy. Refractory epilepsy is a form of epilepsy in which patients typically do not respond to existing available medications and treatment options.

“Nexien is very excited to be working with such a prestigious Medical School. Specifically, we’re working with the Neurology Department which is chaired by a renowned Epileptologist,” said Alex Wasyl, Chief Executive Officer of Nexien.

$NXEN NEWS! Collaboration with Ivy League Medical School!

https://globenewswire.com/news-release/2018/11/28/1658294/0/en/Nexien-BioPharma-And-Ivy-League-University-Medical-School-Collaborate-On-Pre-Clinical-Cannabinoid-Studies.html

Nexien BioPharma Inc. (OTC QB: NXEN) (“Nexien” or the “Company”) announced it is initiating a collaboration with the University Medical School (the “Medical School”) to perform pre-clinical studies using advanced parenteral cannabinoid formulations developed by Nexien, known as NX01R1, NX01R2, and NX01R3 (“formulations”). These formulations target the alleviation of symptoms for the acute treatment and intervention of convulsive disorders and convulsive episodes.

Parenteral administration is a route of administration that includes intramuscular injections of the formulations for optimal dosing and bio-availability. Parenteral administration excludes oral administration of drug formulations.

Nexien will provide the Medical School’s Neurology Lab with specific formulations, in addition to a comprehensive study design developed by the Company’s scientific team. This pre-clinical research will be first performed in rodents, and will initially investigate the Maximum Tolerable Dose (“MTD”) Pharmacokinetic (“PK”) and Pharmacodynamic (“PD”) profiles of advanced cannabinoid-based parenteral formulations.

In November 2017, Nexien filed a provisional patent application with the United States Patent and Trademark Office (USPTO) relating to the use of cannabinoids to treat convulsive disorders, specifically epilepsy and refractory epilepsy. Refractory epilepsy is a form of epilepsy in which patients typically do not respond to existing available medications and treatment options.

“Nexien is very excited to be working with such a prestigious Medical School. Specifically, we’re working with the Neurology Department which is chaired by a renowned Epileptologist,” said Alex Wasyl, Chief Executive Officer of Nexien.

As I Tweeted again today, I added another 17,777 shares at 0.25... So, yes, I completely agree.

This. Will. Be. A. Winner.

Moments before I read your post, I bought another 1,850 at 0.23. :)

I think brains help. :) So many people only want to buy stuff that's being pumped and hyped with non-sense. So many people are too lazy to read ANYTHING on a company, so they just trust strangers on iHub and Twitter.

Garbage stocks/companies run to stupid levels all the time. If someone spent just 15 minutes to read about this management line-up or spent 13 minutes to listen to this great interview today... They should know where the PPS is going to head. Maybe not tomorrow. Maybe not next week. But it's so obvious it's going MUCH higher at some point.

Just added another 7,945 at 0.22 and 0.23... As I've been saying: NO BRAINER.

Where do you see anything about Friedland having shares?

"As of November 29, 2017, Intiva USA Inc. was the record owner of 24,000,000 shares of Common Stock (55.2%%). Jeffrey Friedland owned of record 2,000,000 shares of Common Stock (4.6%), of which 1,333,336 shares were subject to forfeiture provisions, which lapse quarterly over a two-year period beginning December 31, 2017, and is deemed to beneficially own 270,400 shares (0.6%) owned of record by Lane 6552 LLC, which includes 62,400 shares issuable upon the exercise of immediately exercisable warrants. Richard S. Greenberg owned of record 800,000 shares of Common Stock (1.8%), of which 533,336 shares were subject to forfeiture provisions, which lapse quarterly over a two-year period beginning December 31, 2017."

Source: https://www.bamsec.com/filing/121465917007051?cik=1719804

Then, we look at OTCmarkets.com and see a Float of 2,710,691 but I know dating back to October 23rd, Brandy at Standard Registrar told me the Float was reduced and was actually 1,499,026.

That made me wonder -- did Friedland LOSE those shares when he "resigned" as CEO?

Also, check out the FORM 4 mentioning 1,166,667 shares were "Disposed" of after Friedland resigned -- https://www.otcmarkets.com/filing/html?id=12620744&guid=feAbUa0h4YnJT3h

If a Friedland is selling, it would be his wife or kids. But are you saying they would sell out of spite or because they need the money? Because he should know what kind of a fortune is coming.

I'm working on selling some other shares. Would love to free up $5,000+ for NXEN at these levels.

This is seriously a no-brainer. Blows my mind there's not my buying interest. Absolutely blows my mind.

$NXEN NEWS! Uptick Newswire audio interview!

https://upticknewswire.com/featured-interview-ceo-alex-wasyl-of-nexien-biopharma-inc-otcqb-nxen/

Lots of juicy tidbits in this audio interview. Do yourself a favor and have a listen. Then check out the stellar management & advisor line-up -- SoBe Beverage co-founder, guys from Big Pharma like Johnson & Johnson, Teva, Pfizer, etc.

Float is under 5.5 MILLION!

When people wake up... This is absolutely going so much higher. It's only logical, in my opinion.

We've seen crazy runs with OWCP, CNBX, AXIM and we saw how well GWPH did... NXEN is following the GWPH way with, quite frankly, a better solution than Epidiolex from the sounds of it.

$NXEN NEWS! Uptick Newswire audio interview!

https://upticknewswire.com/featured-interview-ceo-alex-wasyl-of-nexien-biopharma-inc-otcqb-nxen/

Lots of juicy tidbits in this audio interview. Do yourself a favor and have a listen. Then check out the stellar management & advisor line-up -- SoBe Beverage co-founder, guys from Big Pharma like Johnson & Johnson, Teva, Pfizer, etc.

Float is under 5.5 MILLION!

When people wake up... This is absolutely going so much higher. It's only logical, in my opinion.

We've seen crazy runs with OWCP, CNBX, AXIM and we saw how well GWPH did... NXEN is following the GWPH way with, quite frankly, a better solution than Epidiolex from the sounds of it.

$NXEN NEWS! Uptick Newswire audio interview!

https://upticknewswire.com/featured-interview-ceo-alex-wasyl-of-nexien-biopharma-inc-otcqb-nxen/

Lots of juicy tidbits in this audio interview. Do yourself a favor and have a listen. Then check out the stellar management & advisor line-up -- SoBe Beverage co-founder, guys from Big Pharma like Johnson & Johnson, Teva, Pfizer, etc.

Float is under 5.5 MILLION!

When people wake up... This is absolutely going so much higher. It's only logical, in my opinion.

We've seen crazy runs with OWCP, CNBX, AXIM and we saw how well GWPH did... NXEN is following the GWPH way with, quite frankly, a better solution than Epidiolex from the sounds of it.

I keep wondering the same thing.

Surely they don't think the CRx acquisition/merger alone was going to send it over $1.25+

So, I still truly suspect they have something big to announce soon and it's just taking a little longer than expected.

Maybe they felt the CRx acquisition + CSE listing was going to help greatly. But, as the Uptick interview mentioned today... They've done all the necessary steps for CSE and they're waiting 100% on the CSE.

I only hoped he meant Thanksgiving because of the extension of the Warrants to end of November.

But I guess we'll find out next week.

To be fair, there's only so much they can do about the share price. You heard the CEO say in the audio interview they're running at full speed to get news out by the Holiday -- we assume that meant Thanksgiving.

But, if said news wasn't ready to be announced by then -- they can't or won't rush or it 'make stuff up'.

Most management who has faith in their company and future also aren't going to worry about trading early on. Traders will come and go.

In all seriousness, I ask you all what you would do if you were Alex Wasyl "to help keep the share price up"? You can't disclose things before they're ready to be announced and you certainly don't want to "pump your stock" either.

Patience PAYS is what I continue to bank on. It's so early in the game here. (I mean, yes, Intiva BioPharma was founded in March 2017 -- but in terms of major announcements... There's plenty up their sleeve.)

That is a great question. Perhaps we will see the Warrants extended into December.

Even if NXEN did drop some large news next week and the stock price ran to $2.00, how many private placement holders are going to exercise their $1.00 warrant with that short of notice.

There's the (simple) paperwork, wire transfer, etc. But now there's a recent history of 'volatility'.

It'll be interesting to see what, if anything, happens next week in terms of announcements and the warrants.

NXEN will need to raise more money for certain, so what better way than with $1.00 Warrants to start with? :)

Still not bad at all.

People get excited when they see stocks with a 50M Float, so the fact that our Outstanding Shares is around 55M should drive them even more bonkers.

It will. It's only a matter of time.

Bring on the news, Alex.

It's a daily thing... FOR NOW. Can't keep going on for ever, as the Float is small enough.

Once we have some big volume days, we'll clean out the dumper.

Hopefully NXEN gets some nice news out before close of Wednesday and it can spark some interest.

I assume he meant Thanksgiving when he said "the holiday".